Sabby Management’s Tempest Therapeutics TPST Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$29.3K Sell
17,856
-160,736
-90% -$388K 0.07% 26
2025
Q4
$513K Buy
+178,592
New +$1.26M 0.74% 12
2025
Q3
Sell
-276,587
Closed -$1.88M 61
2025
Q2
$1.88M Buy
+276,587
New +$1.97M 3.41% 5
2018
Q4
Sell
-87
Closed -$187K 141
2018
Q3
$187K Sell
87
-239
-73% -$574K 0.02% 95
2018
Q2
$866K Sell
326
-174
-35% -$458K 0.13% 65
2018
Q1
$1.19M Buy
500
+295
+144% +$884K 0.14% 56
2017
Q4
$840K Buy
205
+17
+9% +$71.3K 0.08% 84
2017
Q3
$781K Buy
188
+14
+8% +$59.8K 0.05% 87
2017
Q2
$795K Buy
174
+29
+20% +$123K 0.05% 111
2017
Q1
$792K Buy
145
+128
+753% +$596K 0.04% 144
2016
Q4
$74K Hold
17
﹤0.01% 276
2016
Q3
$358K Sell
17
-29
-63% -$525K 0.01% 247
2016
Q2
$704K Buy
+46
New +$1.05M 0.04% 194
2015
Q4
Sell
-102
Closed -$3.36M 367
2015
Q3
$2.53M Sell
102
-19
-16% -$1.28M 0.1% 132
2015
Q2
$10.3M Sell
121
-588
-83% -$53.9M 0.37% 56
2015
Q1
$4.69M Buy
+709
New +$94.4M 0.2% 84
2014
Q3
Sell
-62
Closed -$1.66M 296
2014
Q2
$1.66M Sell
62
-60
-49% -$1.41M 0.07% 115
2014
Q1
$3.19M Buy
122
+70
+135% +$1.98M 0.18% 81
2013
Q4
$1.39M Sell
52
-3
-5% -$82.3K 0.09% 99
2013
Q3
$1.6M Buy
+55
New +$1.95M 0.1% 97

Other funds holding TPST

Sabby Management's TPST Position: Q1 2026 in Review

Sabby Management reduced its Tempest Therapeutics (TPST) stake by 90% in Q1 2026, selling an estimated $388K and leaving 17,856 shares worth $29.3K. The position accounts for 0.07% of the portfolio, ranked #26.

Sabby Management first reported a position in TPST in Q3 2013 and has held it in 20 quarters since. The position peaked at $10.3M in Q2 2015. 22 funds tracked by Wall St. Rank hold TPST as of Q1 2026.

  • Sabby Management held 17,856 shares of Tempest Therapeutics worth $29.3K as of Q1 2026.
  • Sabby Management sold 160,736 Tempest Therapeutics shares in Q1 2026, an estimated $388K.
  • Tempest Therapeutics made up 0.07% of Sabby Management's portfolio in Q1 2026, its #26 holding.
  • Sabby Management first reported a position in Tempest Therapeutics in Q3 2013 and has held it in 20 quarters since.
  • Sabby Management's Tempest Therapeutics position peaked at $10.3M in Q2 2015.
  • 22 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q1 2026.

Based on Sabby Management's 13F filing for Q1 2026, filed 15 May 2026.